Synthetic immunomodulatory nucleic acids for ovarian cancer
Nucleic acids and gene circuits with ovarian cancer-specific promoters enhance tumor specificity by controlling therapeutic output through a split transcription factor, addressing the lack of specificity in current cancer gene therapies and reducing side effects.
Patent Information
- Application Number
- PCT/IB2026/054825
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Current cancer gene therapies lack tumor-targeting specificity, leading to serious side effects and off-target toxicities due to the use of non-specific cancer promoters.
Development of nucleic acids and gene circuits that utilize ovarian cancer-specific promoters to control the expression of a split transcription factor, ensuring therapeutic output is only expressed in the presence of an active transcription factor, thereby enhancing tumor specificity.
The proposed approach achieves higher therapeutic output expression in ovarian cancer cells compared to normal cells, reducing off-target effects and improving treatment specificity.
Smart Images

Figure IMGF000038_0001 
Figure IMGF000019_0001_TABLE 
Figure IMGF000020_0001_TABLE
Abstract
Description
Atty Docket No. 3569.W01WO / 680.3569WO01SYNTHETIC IMMUNOMODULATORY NUCLEIC ACIDS FOR OVARIAN CANCERCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application Serial No.63 / 806,926, filed on May 16, 2025, the disclosure of which is incorporated by reference herein in its entirety.SEQUENCE LISTING
[0002] This application contains a Sequence Listing electronically submitted via Patent Center to the United States Patent and Trademark Office as an XML file entitled“0680.003569WOOL xml” having a size of 14,772 bytes and created on May 14, 2026. The information contained in the Sequence Listing is incorporated by reference herein.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0003] This invention was made with government support under HT9425-23-1-0455 awarded by the Defense Health Agency, Medical Research and Development Branch. The government has certain rights in the invention.BACKGROUND
[0004] Cancer ranks as the second leading cause of death worldwide. However, most of the current treatments have serious side effects and off-target toxicities. Gene therapy, which involves the introduction of a gene encoding a therapeutic protein into a patient’s cells, represents a promising avenue as a cancer therapy. However, most cancer gene therapies have not exhibited high tumor-targeting specificity. One reason is that most cancer-specific promoters used in cancer gene therapy are not sufficiently tumor specific (Nissim et al., Cell 171 (5): 1138-1150 (2017)).
[0005] Therefore, there is a critical need for improved cancer-specific treatments for cancer gene therapy. Immunotherapy is of interest for ovarian cancer, but improved specificity is desired to reduce side effects.Atty Docket No. 3569.W01WO / 680.3569WO01SUMMARY
[0006] The nucleic acids, gene circuits, vectors, compositions, and methods provided herein are expected to address the above need. Provided herein, in one aspect, are nucleic acids for use in treating ovarian cancer including a first nucleic acid sequence encoding a first half of a transcription factor under the control of a first ovarian cancer-specific promoter; a second nucleic acid sequence encoding a second half of the transcription factor under the control of a second ovarian cancer-specific promoter, wherein the first half of the transcription factor and the second half of the transcription factor assemble to form an active transcription factor; and a third nucleic acid sequence encoding a therapeutic output that is only expressed in the presence of the active transcription factor.
[0007] In some embodiments, the first ovarian cancer-specific promoter includes a nucleic acid sequence having least 80% sequence identity to the CC63 MYC promoter (SEQ ID NO:1), the CC83 E2F promoter (SEQ ID NO:2), the CC55 E2F7 promoter (SEQ ID NO:3), the CC65 MYC promoter (SEQ ID NO:4), or the CC72 ZBTB33 promoter (SEQ ID NO:5). In some embodiments, the second ovarian cancer-specific promoter includes a nucleic acid sequence having least 80% sequence identity to the CC63 MYC promoter (SEQ ID NO:1), the CC83 E2F promoter (SEQ ID NO:2), the CC55 E2F7 promoter (SEQ ID NO:3), the CC65 MYC promoter (SEQ ID NO:4), or the CC72 ZBTB33 promoter (SEQ ID NO:5).Typically, the first ovarian cancer-specific promoter includes at most 80% sequence identity to the second ovarian cancer-specific promoter. In some of these embodiments, the first ovarian cancer-specific promoter includes a nucleic acid sequence having least 90% sequence identity to the CC55 E2F7 promoter (SEQ ID NO:3) and the second ovarian cancer-specific promoter includes a nucleic acid sequence having at least 90% identity to the CC63 MYC promoter (SEQ ID NO: 1). In some embodiments, the therapeutic output is under the control of the GALp promoter (SEQ ID NO:6). Typically, the therapeutic output confers sensitivity to a drug or an immunotherapeutic agent, such as CD80, IL-12, CCL21, and / or a Surface T cell Engager (STE).
[0008] The split transcription factor and reassembled active transcription factor is particularly relevant to the disclosed nucleic acids and gene circuits. In some embodiments, the active transcription factor includes an amino acid sequence having at least 80% sequence identity to the Gal4BD domain (SEQ ID NO:8). In some embodiments, the active transcription factor includes an amino acid sequence having at least 80% sequence identity to the Gal4 Activation DomainAtty Docket No. 3569.W01WO / 680.3569WO01(AD) (SEQ ID NO: 9). Typically, the first half of the transcription factor includes a first dimerization domain at its C terminus, and the second half of the transcription factor includes a second dimerization domain at its N terminus.
[0009] In some embodiments, the second half of the transcription factor includes a nuclear localization signal including an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 9. In some embodiments, the first half of the transcription factor includes an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 10 and the second half of the transcription factor includes an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 11.
[0010] In another aspect, the present disclosure relates to a gene expression vector including the nucleic acid described herein. In some embodiments, the gene expression vector includes a plasmid or a virus. In another aspect, the present disclosure relates to a gene circuit including the nucleic acid described herein.
[0011] The nucleic acid, gene expression vector, and / or the gene circuit of the present disclosure may be used in a method of treating ovarian cancer. In some embodiments, the therapeutic output confers sensitivity to a drug or an immunotherapeutic agent, and wherein the method further includes administering to the patient the drug or immunotherapeutic agent. In some embodiments, the first ovarian cancer-specific promoter and / or the second ovarian cancerspecific promoter is more active in ovarian cancer cells than in normal ovarian cells. Typically, the therapeutic output is expressed to a higher level in ovarian cancer cells than in normal ovarian cells.BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Certain illustrations, charts, or flow charts are provided to allow for a better understanding this disclosure. It is to be noted, however, that the drawings illustrate only selected embodiments and are therefore not to be considered limiting of scope. Additional and equally effective embodiments and applications of the present exist.
[0013] FIG. 1 shows a quantification of the strength of each promoter tested in Example 1 in IOSE and OVCAR8 (OV8) cells, as well as the relative strength of each promoter in tumor (OV8) cells compared to normal (IOSE) cells.Atty Docket No. 3569.W01WO / 680.3569WO01
[0014] FIG. 2 shows promoter constructs selectively respond to their cognate transcription factors. (A) Two MYC-responsive promoters (CC63_MYC_v2 and CC65_MYC_v4) exhibit increased output activity upon MYC over expression, whereas an E2F-responsive promoter (CC83_E2F_v2) does not, indicating that CC63_MYC_v2 and CC65_MYC_v4 are selectively responsive to MYC. (B). The E2F-responsive promoter (CC83_E2F_v2) exhibits increased output activity upon E2F overexpression, while the MYC-responsive promoters (CC63_MYC_v2 and CC65_MYC_v4) do not, confirming CC83_E2F_v2's specificity for E2F.
[0015] FIG.3 shows split GAD activator architectures and their activity. (A) Schematic representations of three tested split GAD activator architectures, wherein the SYNZIP domain was attached to the N- and C-termini, the C-termini, or the N-termini of the Gal4BD and AD domains. Activity of each architecture, measured as fluorescence intensity, is shown to the right. (B) A schematic representation of the split N-C GAD activator architecture and a GAD promoter-expressed mKate construct. Fluorescence of mKate in cells treated with one or both halves of the split N-C GAD activator, shown as paired brightfield and fluorescence microscopy images and quantified on the right.
[0016] FIG. 4 shows expression strength of two split N-C GAD activators using different SYNZIP pairs. (A) Expression strength of split N-C GAD activators using SYNZIP1 / SYNZIP2 dimerization domains or SYNZIP5 / SYNZIP12 dimerization domains in OV8 and IOSE cells. (B) Fluorescence microscopy and brightfield images of OV8 and IOSE cells treated with the split N-C GAD SYNZIP5 / SYNZIP12 activator.
[0017] FIG. 5 shows the activity of gene circuits combining different promoters. (A) Activity of gene circuits in OV8 cells, chosen to be representative of ovarian cancer cells. (B) Activity of gene circuits in IOSE cells, chosen to be representative of normal ovarian cells.
[0018] FIG. 6 shows the activity of gene circuits combining different promoters in OV8 cells and IOSE cells. (A) A heat map showing the relative activity of each gene circuit shown in FIG. 6 in OV8 and IOSE cells. (B) Comparison of the activity fold differences of the top five gene circuits shown in FIG. 5 relative to a previously reported gene circuit (pLN484-pLN397).
[0019] FIG. 7 shows the normalized activity of newly identified promoters relative to previously described promoters. (A) The newly developed promoters exhibited higher activity compared to the two previously described promoters (Cell-E2F1 and Cell-Myc). (B) The new promoters also displayed greater tumor specificity relative to the earlier promoters.Atty Docket No. 3569.W01WO / 680.3569WO01
[0020] FIG. 8 shows tumor size and survival of mice implanted with the BPPNM ovarian cancer tumors and treated with an ovarian cancer-specific gene circuit. At 11 days, all mice showed similar tumor burden as measured by luminescence. At 32 days, mice treated with the gene circuit showed significantly lower tumor burden than mice treated with the control.
[0021] FIG. 9 shows quantification of tumor size from mice treated with different ovarian cancer-specific gene circuits or vehicle control (PBS).
[0022] FIG. 10 shows tumor size of mice treated with different ovarian cancer-specific gene circuits or vehicle control (PBS). Mice treated with GR8, GR6, GR2, and GR7 exhibited moderate to high tumor burden. Mice treated with GR4 exhibited the lowest tumor burden of any treatment group.
[0023] FIG. 11 shows that the CC63_MYC_v2 and CC72_ZBTB33_v2 promoters, as well as the AND gate constructed from these two promoters, demonstrate superior tumor specificity compared to the constitutive CMV promoter. In contrast, the CMV promoter shows potential for off-target expression in the spleen, intestine, and peritoneal wall. (A) Representative IVIS luminescence imaging results showing reporter gene (Luciferase) expression driven by various gene expression cassettes. The synthetic tumor-specific promoters and the AND gate display enhanced specificity. For mice treated with MYC_v2, SBTB33_v2, or the AND gate, the highest level of luminescence was observed in the tumor, and minimal expression was observed in other measured tissues. Some luminescence was observed in intestine and IP wall in mice treated with MYC-v2. Mice treated with the CMV construct exhibited luminescence in spleen, intestine, IP wall, and tumor. (B) Quantification of the luminescence data shown in panel A. (C) Both the tumor-specific promoters and the AND gate drove strong output expression levels, comparable to that achieved by the CMV promoter.DETAILED DESCRIPTION
[0024] The singular forms “a”, “an” and “the” include plural reference unless the context clearly dictates otherwise. The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and / or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”Atty Docket No. 3569.W01WO / 680.3569WO01
[0025] Wherever any of the phrases “for example,” “such as,” “including” and the like are used herein, the phrase “and without limitation” is understood to follow unless explicitly stated otherwise. Similarly, “an example,” “exemplary” and the like are understood to be nonlimiting.
[0026] The term “substantially” allows for deviations from the descriptor that do not negatively impact the intended purpose. Descriptive terms are understood to be modified by the term “substantially” even if the word “substantially” is not explicitly recited.
[0027] The terms “comprising” and “including” and “having” and “involving” (and similarly “comprises”, “includes,” “has,” and “involves”) and the like are used interchangeably and have the same meaning.
[0028] As used herein, the term “about” can refer to approximately, roughly, around, or in the region of. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term “about” is used herein to modify a numerical value above and below the stated value by a variance of 10 percent up or down (higher or lower). “About” can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term “about.”
[0029] The term “approximately” as used herein refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value (except where such number would exceed 100% of a possible value).
[0030] The term "promoter" as used herein refers to a nucleic acid that facilitates, directly or indirectly, the transcription of a corresponding nucleic acid to which it is operatively linked. A promoter may function alone to facilitate transcription, or it may act in concert with one or more other regulatory units (e.g., enhancers and silencers that may be present in the nucleic acids or the vector). Promoters are located near the transcription start sites of nucleic acid coding sequences, on the same strand and upstream on the DNA (towards the 5' region of the sense strand).
[0031] The term “synthetic” as used herein when referring to proteins or nucleic acids refers to a protein or nucleic acid that is not naturally found in an organism (i.e., non-naturally occurring).Atty Docket No. 3569.W01WO / 680.3569WO01
[0032] The term “non-cancerous” as used herein refers to a cell that is not dividing in an uncontrolled fashion, i.e., a cell that would arrest at a cell cycle checkpoint during mitosis.
[0033] The term “nucleic acid” as used herein refers to a polymer of nucleotides that contain a nucleoside (a nucleobase and a five-carbon sugar) and a phosphate. The term nucleotide includes nucleosides that have a ribose sugar (i.e., a ribonucleotide that forms ribonucleic acid, RNA) or a 2’ -deoxyribose sugar (i.e., a deoxyribonucleotide that forms deoxyribonucleic acid, DNA).Nucleotides serve as the monomeric units of nucleic acid polymers or polynucleotides. The four nucleobases in DNA are guanine (G), adenine (A), cytosine (C), and thymine (T). The four nucleobases in RNA are guanine (G), adenine (A), cytosine (C), and uracil (U). Nucleic acids are linear chains of nucleotides (e.g., at least 3 nucleotides) chemically bonded by a series of ester linkages between the phosphoryl group of one nucleotide and the hydroxyl group of the sugar (i.e., ribose or 2 ’-deoxyribose) in the adjacent nucleotide. The term “nucleic acid coding sequence” as used herein refers to a segment of nucleic acids that encodes a therapeutic nucleic acid, peptide, polypeptide, or protein.
[0034] The term “transcription factor binding site” or “TFBS” as used herein refers to a nucleic acid sequence contained in the synthetic promoters disclosed herein to which a transcription factor binds to facilitate expression of a nucleic acid coding sequence operatively linked to the promoter.
[0035] The terms “preferentially,” “preferentially driven” or “preferentially driven transcription” as used herein refer to the increased expression of a nucleic acid operatively linked to a synthetic promoter, i.e., a vector comprising the synthetic promoter, in an ovarian cancer cell relative to the level of expression of the same vector in a non-cancerous ovarian cell. Thus, a synthetic promoter that preferentially drives expression of an operatively linked nucleic acid in an ovarian cancer cell may drive expression of the nucleic acid in both an ovarian cancer cell and a non-cancerous ovarian cell (e.g., immortalized ovarian surface epithelium (IOSE) cells), but the level of expression of the nucleic acid will be higher in the ovarian cancer cell relative to the non-cancerous ovarian cell. Preferentially driven transcription in ovarian cancer cells may also be referred to herein in terms of a “fold-increase” in activity of the synthetic promoter in an ovarian cancer cell relative to the activity of the synthetic promoter in a non-cancerous ovarian cell.Atty Docket No. 3569.W01WO / 680.3569WO01
[0036] The term "operatively linked" as used herein is to be understood that a nucleic acid coding sequence disposed relative to the synthetic promoter such that the synthetic promoter facilitates the transcription of the nucleic acid coding sequence.
[0037] The term “protein” as used herein refers to a polymer of amino acid residues, each of which are organic compounds consisting of an amino functional group and a carboxylic acid functional group, where the amino acid residues are bonded together by peptide bonds. Broadly, the therapeutic protein may be any such protein that as an expression product, may exert an anticancer (e.g., immune stimulatory) effect, at least in the context of ovarian cancer.
[0038] The term “derived from” as used herein when referring to proteins and nucleic acids refers to a protein or nucleic acid that originates from another, parental protein, or nucleic acid. The derived protein or nucleic acid has a sequence that may be identical to the parental sequence, may be a portion of the parent sequence, or may be a variant of the parent protein or nucleic acid in that it differs from the sequence of the parent. Variants may include amino acid and nucleotide substitutions, insertions, or deletions. Thus, for example, an amino acid sequence derived from a parent sequence may be identical for a specific range of amino acids of the parent but does not include amino acids outside that specific region.
[0039] As used herein “sequence identity” refers to the extent to which two optimally aligned nucleic acid sequences are invariant throughout a window of alignment of components, e.g., nucleotides. “Identity” can be readily calculated by known methods including, but not limited to, those described in: Computational Molecular Biology (Lesk, A. M., ed.) Oxford University Press, New York (1988); Biocomputing: Informatics and Genome Projects (Smith, D. W., ed.) Academic Press, New York (1993); Computer Analysis of Sequence Data, Part I (Griffin, A. M., and Griffin, H. G, eds.) Humana Press, New Jersey (1994); Sequence Analysis in Molecular Biology (von Heinje, G, ed.) Academic Press (1987); and Sequence Analysis Primer (Gribskov, M. and Devereux, J., eds.) Stockton Press, New York (1991).
[0040] As used herein, the term “percent sequence identity” or “percent identity” refers to the percentage of identical nucleotides in a linear polynucleotide sequence of a reference (“query”) nucleic acid (or its complementary strand) as compared to a test (“subject”) nucleic acid (or its complementary strand) when the two sequences are optimally aligned. Percent sequence identity may be determined, when the compared sequences are aligned for maximum correspondence, asAtty Docket No. 3569.W01WO / 680.3569WO01measured using a sequence comparison algorithm described below and as known in the art, or by visual inspection.
[0041] For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters. Optimal alignment of sequences for aligning a comparison window are well known to those skilled in the art and may be conducted by tools such as the local homology algorithm of Smith and Waterman, the homology alignment algorithm of Needleman and Wunsch, the search for similarity method of Pearson and Lipman, and optionally by computerized implementations of these algorithms such as GAP, BESTFIT, FASTA, and TFASTA available as part of the GCG WISCONSIN PACKAGE (Accelrys Inc., San Diego, CA). Alignment of sequences may be analyzed using a Burrows-Wheeler transform such as BOWTIE open-source software available from github.com / BenLangmead / bowtie. An “identity fraction” for aligned segments of a test sequence and a reference sequence is the number of identical components which are shared by the two aligned sequences divided by the total number of components in the reference sequence segment, i.e., the entire reference sequence or a smaller defined part of the reference sequence. Percent sequence identity is represented as the identity fraction multiplied by 100.
[0042] ‘ ‘Percent identity” may also be determined using BLASTX version 2.0 for translated nucleotide sequences and BLASTN version 2.0 for polynucleotide sequences. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., 1990).These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; alwaysAtty Docket No. 3569.W01WO / 680.3569WO01> 0) and N (penalty score for mismatching residues; always < 0). Extension of the word hits in each direction are halted when the cumulative alignment score falls off by the quantity X from its maximum achieved value, the cumulative score goes to zero or below due to the accumulation of one or more negative-scoring residue alignments, or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, an expectation (E) of 10, a cutoff of 100, M=5, N^4, and a comparison of both strands.
[0043] The term “cytokine” refers to low molecular weight extracellular polypeptides / gly coproteins that promote, modulate, and regulate the immune response (i.e., increase or decrease activity, differentiation, or proliferation).
[0044] The term “tumor suppressor” as used herein refers to a gene product that reduces cancer cell growth.
[0045] The term “signal peptide” as used herein refers to a short (e.g., 5-30 or 10-100 amino acids long) stretch of amino acids that directs the transport of the therapeutic protein during translation.
[0046] As used herein, the term “lentiviral vector” refers to an infectious lentiviral particle. Lentivirinae (lentiviruses) is a subfamily of enveloped retroviridae (retroviruses), that is distinguishable from other viruses by virion structure, host range, and pathological effects. An infectious lentiviral particle is capable of invading a target host cell, including infecting, and transducing non-dividing cells and immune cells.
[0047] The term “effective amount” as used herein refers to a sufficient amount of vector to provide the desired effect, e.g., the amount of a vector to introduce the transcriptional unit into an ovarian cancer cell, in vitro or in vivo, to express the nucleic acid coding sequence.
[0048] The term “subject” (or “patient”) as used herein includes all members of the animal kingdom prone (or disposed) to or suffering from ovarian cancer. In some embodiments, the subject is a human. Therefore, a subject “having a cancer” or “in need of’ treatment according to the present disclosure broadly embraces subjects who have been positively diagnosed, including subjects having active disease who may have been previously treated with one or more rounds of therapy, and subjects who are not currently being treated (e.g., in remission) but who might still be at risk of relapse, and subjects who have not been positively diagnosed but who are predisposed to ovarian cancer (e.g., on account of the basis of prior medical history and / or familyAtty Docket No. 3569.W01WO / 680.3569WO01medical history, or who otherwise present with a one or more risk factors such that a medical professional might reasonably suspect that the subject was predisposed to ovarian cancer).
[0049] The terms “treat”, “treating”, and “treatment” as used herein refer to any type of intervention, process performed on, or the administration of an active agent to the subject in need thereof with the therapeutic objective (“therapeutic effect”) of reversing, alleviating, ameliorating, inhibiting, diminishing, slowing down, arresting, stabilizing, or preventing the onset, progression, development, severity or recurrence of a symptom, complication or condition, or biochemical indicia associated with ovarian cancer.
[0050] The term “ovarian cancer” as used herein encompasses cancers that develop from cells that form the ovaries and associated tissues, including ovarian, fallopian, and peritoneal tissues. Ovarian cancers include ovarian carcinomas (e.g., epithelial ovarian carcinomas, low-grade serous ovarian carcinoma (LGSOC), high-grade serous ovarian carcinoma (HGSOC), serous adenocarcinomas, ovarian clear cell carcinoma (OCCC), primary squamous cell carcinoma (SCC) of the ovary, endometrioid carcinoma, and endometrioid adenocarcinomas), ovarian germ cell tumors, ovarian stromal cell tumors, and leiomyosarcomas.Ovarian Cancer and Ovarian Cancer-Specific Promoters
[0051] The present disclosure relates to, in part, promoters having higher activity in ovarian cancer cells than in some other cells, such as healthy ovarian cells. A promoter having higher activity in ovarian cancer cells than in healthy ovarian cells is sometimes referred to herein as an ovarian cancer-specific promoter.
[0052] Example 1 describes that ovarian cancer-specific promoters may be identified by comparing expression of a common output under the control of a promoter of interest in healthy ovarian cells and ovarian cancer cells. Different promoters may exhibit different levels of expression in different ovarian cancer cells. Therefore, a promoter that is considered to be an ovarian cancer- specific promoter may not always exhibit high levels of expression in all ovarian cancer cells.
[0053] In some embodiments, an ovarian cancer- specific promoter is the CC63 MYC promoter (SEQ ID NO:1). In some embodiments, an ovarian cancer-specific promoter has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the CC63 MYC promoter (SEQ ID NO: 1).Atty Docket No. 3569.W01WO / 680.3569WO01
[0054] In some embodiments, an ovarian cancer-specific promoter is the CC83 E2F promoter (SEQ ID NO:2). In some embodiments, an ovarian cancer- specific promoter has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the CC83 E2F promoter (SEQ ID NO:2).
[0055] In some embodiments, an ovarian cancer- specific promoter is the CC55 E2F7 promoter (SEQ ID NO:3). In some embodiments, an ovarian cancer-specific promoter has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the CC55 E2F7 promoter (SEQ ID NO:3).
[0056] In some embodiments, an ovarian cancer- specific promoter is the CC65 MYC promoter (SEQ ID NO:4). In some embodiments, an ovarian cancer-specific promoter has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the CC65 MYC promoter (SEQ ID NO:4).
[0057] In some embodiments, an ovarian cancer-specific promoter is the CC72 ZBTB33 promoter (SEQ ID NO:5). In some embodiments, an ovarian cancer-specific promoter has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the CC72 ZBTB33 promoter (SEQ ID NO: 5).
[0058] In one aspect, the present disclosure relates to methods of expressing a nucleic acid coding sequence in an ovarian cancer cell. The nucleic acid coding sequence is typically part of a nucleic acid such as a gene circuit described herein. The method includes contacting the ovarian cancer cell with the nucleic acid or a vector including the nucleic acid. In some embodiments, the ovarian cancer cell is contacted with the vector in vitro. In some embodiments, a subject in need thereof is administered a pharmaceutical composition containing the vector and a pharmaceutically acceptable carrier (i.e., in vivo) to treat ovarian cancer.Nucleic acids and Gene Circuits
[0059] A nucleic acid for use in methods and compositions of the present application typically includes a first nucleic acid sequence encoding a first half of a transcription factor under the control of a first promoter, and a second nucleic acid sequence encoding a second half of a transcription factor under the control of a second promoter. The first half of the transcription factor and the second-half of the transcription factor typically assemble to form an active transcription factor. In addition, the nucleic acid typically includes a third nucleic acid sequenceAtty Docket No. 3569.W01WO / 680.3569WO01encoding a therapeutic output that is only expressed in the presence of the active transcription factor.
[0060] Typically, the first promoter and the second promoter are considered to be “ovarian cancer-specific” promoters. By “ovarian cancer-specific” is meant that the promoter is highly active in one or more types of ovarian cancer cells. The ovarian cancer- specific promoter is often more active in ovarian cancer cells than in comparable normal cells, such as healthy ovarian cells.
[0061] As is described in the examples, preparation of a split transcription factor is nontrivial. To prepare the split transcription factor exemplified herein, the GAL promoter was split into a GAL4 Binding Domain (GAL4BD) and an Activation Domain (AD). Preparation of the GAL4BD / AD split transcription factor is described in Example 2. To assemble the full promoter from split components, a dimerization domain was added to each half of the split transcription factor. While described in the context of the SYNZIP dimerization system, other dimerization domains are contemplated for use in the present system. Here, the SYNZIP5 (SZ5) domain was prepared as a fusion protein with the GAL4BD, and the SYNZIP12 (SZ12) domain was prepared as a fusion protein with the AD. Accordingly, a nucleic acid used herein may include one or both of a nucleic acid sequence encoding GAL4-SZ5 (SEQ ID NO: 10) and a nucleic acid sequence encoding SZ12-AD (SEQ ID NO: 11). Alternatively, multiple nucleic acids may be provided in combination, such as a first nucleic acid encoding the first half of a transcription factor (e.g., GAL4-SZ5, SEQ ID NO: 10) and a second nucleic acid encoding the second half of a transcription factor (e.g., SZ12-AD, SEQ ID NO: 11).
[0062] The nucleic acid includes a sequence encoding a first half of a split transcription factor. Typically, the first half of the split transcription factor includes an amino acid sequence having at least 80% sequence identity to the GAL4BD (SEQ ID NO: 8). The nucleic acid may encode an amino acid sequence including the amino acid sequence of Gal4BD (SEQ ID NO: 8). The nucleic acid may encode an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to the amino acid sequence of Gal4BD (SEQ ID NO: 8).
[0063] The first half of the transcription factor may also include an amino acid sequence of a first dimerization domain. The first dimerization domain may have at least 80% sequence identity to SYNZIP5 (SEQ ID NO: 12). The nucleic acid may encode the amino acid sequence ofAtty Docket No. 3569.W01WO / 680.3569WO01the first dimerization domain. The nucleic acid may encode an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to the amino acid sequence of SYNZIP5 (SEQ ID NO: 12).Typically, the first dimerization domain is at the C terminus of the first half of the split transcription factor. Thus, the nucleic acid may include a first nucleotide sequence encoding the first half of a transcription factor and a second nucleotide sequence encoding the first dimerization domain, wherein the second nucleotide sequence is 3' of the first nucleotide sequence.
[0064] The nucleic acid may encode an amino acid sequence including the amino acid sequence of Gal4BD-SZ5 (SEQ ID NO: 10). The nucleic acid may encode an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to the amino acid sequence of Gal4BD-SZ5 (SEQ ID NO: 10).
[0065] The nucleic acid includes a sequence encoding a second half of a split transcription factor. Typically, the second half of the split transcription factor includes an amino acid sequence having at least 80% sequence identity to AD (SEQ ID NO:7). The nucleic acid may encode an amino acid sequence including the amino acid sequence of AD (SEQ ID NO:7). The nucleic acid may encode an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to the amino acid sequence of AD (SEQ ID NO: 7).
[0066] The second half of the transcription factor may also include an amino acid sequence of a second dimerization domain. Typically, the first dimerization domain and the second dimerization domain are capable of dimerizing to form a complex. The second dimerization domain may have at least 80% sequence identity to SYNZIP12 (SEQ ID NO: 13). The nucleic acid may encode the amino acid sequence of the second dimerization domain. The nucleic acid may encode an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to the amino acid sequence of SYNZIP12 (SEQ ID NO: 13). Typically the second dimerization domain is at the N terminus of the second half of the split transcription factor. Thus, the nucleic acid may include a first nucleic acid sequence encoding the second half of the split transcription factor and a second nucleic acid sequence encoding the second dimerization domain, wherein the second nucleic acidAtty Docket No. 3569.W01WO / 680.3569WO01sequence is 5' of the first nucleic acid sequence. When discussed in combination with the nucleic acid sequences encoding the first half of the transcription factor and the first dimerization, the nucleic acid sequences encoding the second half of the transcription factor and the second dimerization domain may be referred to as the third nucleic acid sequence and the fourth nucleic acid sequence, respectively.
[0067] The second half of the split transcription factor may additionally include an amino acid sequence of a nuclear localization sequence (NLS). While different NLS sequences are contemplated, the NLS from VP16ADg (SEQ ID NO: 10) is described herein. The nucleic acid may include a sequence encoding the amino acid sequence of SYNZIP12-AD-NLS (SEQ ID NO: 14). The nucleic acid may encode an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to the amino acid sequence of SYNZIP12-AD-NLS (SEQ ID NO: 14).
[0068] To achieve improved specificity of expression of a therapeutic output, each half of the split transcription factor may be expressed from a different promoter. While certain promoters are described herein as having specificity to ovarian cancer cells, some promoters may still have low levels of expression in other cells (e.g., off-target expression). However, the off-target expression profiles of different ovarian cancer-specific promoters are typically different. Thus, by making expression of a therapeutic output dependent on activity of two different ovarian cancer-specific promoters, off-target expression may be reduced. Cells in which only one promoter is active typically will not have expression of the therapeutic output. To prepare a construct wherein expression of a therapeutic output is dependent on activity of two promoters, each half of the split transcription factor may be expressed from a different promoter.
[0069] Typically, a nucleic acid includes a first sequence including the first half of a split transcription factor under control of a first promoter and a second sequence including the second half of a split transcription factor under control of a second promoter. Alternatively, a first nucleic acid may include the first sequence, and a second nucleic acid may include the second sequence. Typically, each of the first promoter and the second promoter is an ovarian cancerspecific promoter.
[0070] In some embodiments, the first promoter is the CC63 MYC promoter (SEQ ID NO:1). In some embodiments, the first promoter has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the CC63 MYCAtty Docket No. 3569.W01WO / 680.3569WO01promoter (SEQ ID NO:1). In some embodiments, the first promoter is the CC83 E2F promoter (SEQ ID NO:2). In some embodiments, the first promoter has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the CC83 E2F promoter (SEQ ID NO:2). In some embodiments, the first promoter is the CC55 E2F7 promoter (SEQ ID NO:3). In some embodiments, the first promoter has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the CC55 E2F7 promoter (SEQ ID NO:3). In some embodiments, the first promoter is the CC65 MYC promoter (SEQ ID NO: 4). In some embodiments, the first promoter has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the CC65 MYC promoter (SEQ ID NO:4). In some embodiments, the first promoter is the CC72 ZBTB33 promoter (SEQ ID NO: 5). In some embodiments, the first promoter has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the CC72_ZBTB33 promoter (SEQ ID NO:5).
[0071] In some embodiments, the second promoter is the CC63 MYC promoter (SEQ ID NO:1). In some embodiments, the second promoter has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the CC63 MYC promoter (SEQ ID NO:1). In some embodiments, the second promoter is the CC83 E2F promoter (SEQ ID NO: 2). In some embodiments, the second promoter has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the CC83 E2F promoter (SEQ ID NO:2). In some embodiments, the second promoter is the CC55 E2F7 promoter (SEQ ID NO:3). In some embodiments, the second promoter has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the CC55 E2F7 promoter (SEQ ID NO:3). In some embodiments, the second promoter is the CC65 MYC promoter (SEQ ID NO:4). In some embodiments, the second promoter has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the CC65 MYC promoter (SEQ ID NO:4). In some embodiments, the second promoter is the CC72 ZBTB33 promoter (SEQ ID NO: 5). In some embodiments, the second promoter has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the CC72_ZBTB33 promoter (SEQ ID NO:5).Atty Docket No. 3569.W01WO / 680.3569WO01
[0072] Typically, the first promoter and the second promoter include different sequences. The first promoter typically includes less than 100% sequence identity to the second promoter. The first promoter may have at most 80%, at most 70%, at most 60%, at most 50%, at most 40%, at most 30%, at most 20%, at most 10% or at most 5% sequence identity to the second promoter.
[0073] The transcription factor used will typically influence the promoter used to express a downstream output, such as a therapeutic output. Certain transcription factors may be more active or exclusively active in combination with certain promoters. For example, the GALp promoter (SEQ ID NO: 6) is typically used with the GAL4 activator. The GALp promoter may be used in combination with the split GAL4 activator, such as the GAL4-SZ5 and SZ12-AD system. The promoter used with the therapeutic output typically includes a nucleic acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the GALp promoter (SEQ ID NO: 6). Accordingly, a nucleic acid may include a nucleic acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the GALp promoter (SEQ ID NO:6).
[0074] The term “gene circuit” is used herein to describe one or more nucleic acids that perform a logical function within a cell, most typically an AND gate. In other words, a gene circuit typically includes at least two nucleic acid sequences, wherein the at least two nucleic acid sequences act in concert in a cell to result in expression of a output that would not be expressed if the cell included only one or only a subset of the nucleic acid sequences.
[0075] Typically, a gene circuit of the present disclosure includes three nucleic acid sequences. The first nucleic acid sequence encodes a first half of a split transcription factor, such as Gal4BD-SZ5 (SEQ ID NO: 10), under the control of a first promoter. The second nucleic acid encodes a second half of a split transcription factor, such as SYNZIP12-AD-NLS (SEQ ID NO: 14), under the control of a second promoter. The third nucleic acid encodes a therapeutic output under the control of a promoter corresponding to the split transcription factor, such as the GALp promoter (SEQ ID NO: 6).
[0076] A gene circuit may include any of the nucleic acids described herein. The different nucleic acid sequences of the gene circuit may be provided as components of a single nucleic acid, or they may be provided as separate nucleic acids.Atty Docket No. 3569.W01WO / 680.3569WO01Therapeutic outputs
[0077] The nucleic acid typically encodes a therapeutic output (e.g., payload) such as a therapeutic nucleic acid, peptide, polypeptide, or protein. In some embodiments, the nucleic acid coding sequence is a reporter. In some embodiments, the nucleic acid coding sequence encodes a therapeutic protein or a therapeutic nucleic acid. In some embodiments, the therapeutic protein is a transcription factor, a surface T cell engager (STE), a cytokine, a tumor suppressor, or a checkpoint inhibitor.
[0078] The therapeutic output may confer sensitivity to a drug or an immunotherapeutic agent. Typically, the therapeutic output is useful in treating ovarian cancer.
[0079] In some embodiments, the therapeutic protein is a STE. In some embodiments, the STE is a fusion protein containing an antibody fragment, e.g., a single-chain variable antibody fragment (scFv), that binds CD3 and a membrane anchor domain. The membrane anchor domain localizes the STE to the cell plasma membrane and may be any transmembrane domain. In some embodiments, the antibody fragment of the STE fusion protein is derived from a commercially available anti-CD3 antibody, antibody fragment, or derivative thereof. The names of anti-CD3 antibodies from which the therapeutic protein may be derived are provided at the NCBI and FDA Global Substance Registration System (GSRS), with accession numbers set forth herein, include, e.g., blinatumomab (available under the tradename BLINCYTO; NCBI 6AL5), catumaxomab (available under the tradename REMOVAB; NCBI 4DZ8), flotetuzumab (MGD006; GSRS 0AHT0IC02G), muromonab-CD3 (available under the tradename ORTHOCLONE OKT3 ;NCBI 8F0L), otelixizumab (ChAglyCD3, TRX4; GSRS I5HF2X04PB), tebentafusp (available under the tradename KIMMTRAK; GSRS N658GY6L3E), teplizumab (available under the tradename TZIELD; GSRS S4M959U2IJ), and visilizumab (available under the tradename NUVION; GSRS H18SKU3289). In some embodiments, the membrane anchor domain of the STE fusion protein is derived from the Duffy antigen / receptor for chemokines (DARC). DARC is also known as Atypical Chemokine Receptor 1 (Duffy blood group) (ACKR1; NCBI gene ID 2532).
[0080] In some embodiments, the therapeutic protein is a cytokine or a non-naturally occurring variant or fragment thereof that binds to the cytokine’s cognate target. Representative examples of cytokines include chemokines, interferons (IFNs), interleukins (Ils), lymphokines and tumor necrosis factors (TNFs). Cytokine variants are non-naturally occurring proteinsAtty Docket No. 3569.W01WO / 680.3569WO01capable of binding to a cytokine receptor on an immune cell and initiating signal transduction through that receptor to achieve substantially the same effect as the naturally occurring cytokine.
[0081] In embodiments wherein the therapeutic protein is a cytokine, or a non-naturally occurring variant or fragment thereof, the cytokine may be derived from IL- la, IL-1 P, IL-2, IL-5, IL-12, IL-17, CCL21, TNF-a, IFN-a, IFN-P, or IFN-y. The amino acid sequences of additional representative cytokines from which the therapeutic protein may be derived are provided at the NCBI Accession numbers set forth in Table 1.Table 1: Examples of Therapeutic Proteins of InterestGene Name Gene Symbols Protein Accession No(s).Attractin ATRN, Attractin, DPPT-L, NP_001193976, NP_001310261,KIAA0548, MGCA NP 647537, NP 647538 Colony stimulating factor CSF, CSF2, GM-CSF, NP_0007492 GMCSFCD40 molecule Bp50, CD40, CDW40, XP_005260676, XP_011527411,CDw40, P50, TNFRSF5 XP_016883624, XP_016883625,XP_047296557, NP_001241, NP_001289682, NP_001309350, NP_001309351, NP_001349687, NP 690593CD80 molecule B7, B7-1, B7.1, BB1, NP_005182CD28LG, CD28LG1, CD80,LAB7CD86 molecule B7-2, B7.2, B70, BU63, NP_001193853, NP_001193854,CD28LG2, CD86, FUN-1, NP_008820, NP_787058, LAB72 NP 795711Colony stimulating factor CSF, CSF2, GM-CSF, NP_0007492 GMCSFCyclic GMP-AMP C6orfl50, CGAS, H-CGAS, XP_047274115, NP_001397840, synthase MB21D1 NP 612450C-X-X Motif chemokine CXCL1, FSP, GRO, GR01, NP_001502ligand 1 GROA, GROa, MGSA,MGSA-A, NAP-3, SCYB1Fms related receptor FL, FLG3L, FLT3, FLT3L, XP_006723179, XP_011524977, tyrosine kinase 3 ligand FLT3LG, Flt3, Flt3L, Ligand XP_011524978, XP_011524979,XP_011524980, XP_011524982, XP_047294475, XP_047294476, XP_047294477, XP_047294478, XP_047294479, NP_001191431, NP_001191432, NP_001265566,NP 001265567, NP 001450Atty Docket No. 3569.W01WO / 680.3569WO01Gasdermin d DF5L, DFNA5L, FKSG10, NP_001159709, NP_079012FLJ12150, GSDMD,GSDMDC1, GasderminIntercellular adhesion BB2, CD54, ICAM-1, NP_000192molecule 1 ICAM1, P3.58Interferon gamma IFG, IFI, IFN-Gamma, IFNG, NP_000610IMD69Interleukin 1 alpha ALPHA, Alpha, IL-1, IL-1A, NP_000566, NP_001358483IL1, IL1-ALPHA, ILIA,IL1F1Interleukin 1 beta Catabolin, IL-1, IL-1 Beta, XP_047300131, NP_000567IL-1B, IL1-BETA, IL1B,IL1F2, ILlbetaInterleukin 2 IL-2, IL2, TCGF NP 000577Interleukin 3 IL-3, IL3, MCGF, NP_000579MGC79398, MGC79399,MULTLCSFInterleukin 4 BCGF-1, BCGF1, BSF-1, NP_000580, NP_001341919, BSF1, IL-4, IL4, MGC79402 NP 758858Interleukin 5 EDF, IL-5, IL5, TRF XP_005272045, XP_011541675,XP 047273104, NP 000870 Interleukin 7 IL-7, IL7 XP_011515824, XP_011515825,XP_047277721, XP_047277722, XP_047277723, XP_047277724, NP_000871, NP_001186815, NP 001186816, NP 001186817 Interleukin 12 receptor CD212, IL-12RB1, IL12R, XP_006722804, XP_011526268, subunit beta 1 IL12RB, IL12RB1, IMD30 XP_011526269, XP_011526270,XP_011526271, XP_011526272, XP_011526273, XP_011526274, XP_011526277, XP_011526278, XP_011526279, XP_016882251, XP_047294723, XP_047294724, XP_047294725, XP_047294726, XP_047294727, XP_047294728, XP_047294729, XP_047294730, XP_047294731, NP_001276952, NP_001276953, NP_005526, NP 714912Interleukin 12b CLMF, CLMF P40, CLMF2, NP_002178IL-12B, IL12, IL12B, IMD28,IMD29, NKSF, NKSF2Interleukin 13 ALRH, BHR1, IL-13, IL13, NP_001341920, NP_001341921,MGC116786, MGC116788, NP_001341922, NP_002179MGC116789, NC30, P600Atty Docket No. 3569.W01WO / 680.3569WO01Interleukin 17a CTLA-8, CTLA8, IL- 17, IL- NP_00218117A, IL17, IL17A, ILA17Interleukin 17f CANDF6, IL-17F, IL17A, XP_011512578, NP_443104IL17F, ML-1, ML1Interleukin 23 subunit IL-23, IL-23-A, IL-23 A, IL- NP_057668alpha 23pl9, IL23A, IL23P19, P19,SGRFInterleukin 32 IL-32, IL-32beta, IL32, NK4, NP_001012649, NP_001012650,TAIF, TAIFa, TAIFb, TAIFc, NP_001012651, NP_001012652, TAIFd NP_001012653, NP_001012654,NP_001012736, NP_001295007, NP_001356516, NP_001356517, NP_001356518, NP_001356519, NP_001356520, NP_001356521, NP_001356522, NP_001356524, NP_001356525, NP_001363852, NP 004212Matrix metallopeptidase 48, CLG1, EC 3.4.24, HNC, XP_011541136, XP_011541137, 8 MMP-8, MMP8, PMNL-CL XP_047282921, XP_047282922,NP_001291370, NP_001291371, NP 002415Transforming growth CED, DPD1, IBDIMDE, XP_011525544, NP_000651 factor beta 1 LAP, TGF-Betal, TGFB,TGFB1, TGFbetaTransforming growth Cetermin, G-TSF, LDS4, NP_001129071, NP_003229 factor beta 2 Polyergin, TGF-Beta2,TGFB2Transforming growth ARVD, ARVD1, LDS5, NP_001316867, NP_001316868, factor beta 3 RNHF, TGF-Beta3, TGFB3 NP 003230Tumor necrosis factor Cachectin, DIF, TNF, TNF- A, NP_000585TNF-Alpha, TNFA, TNFSF2,TNLG1FTnf superfamily member CD134L, CD252, GP34, XP_011508266, XP_016857717, 4 Gp34, OX-40L, OX40L, XP_047285852, XP_047285858,0X40L, TNFSF4, TNLG2B, XP_047285864, NP_001284491, TXGP1 NP 003317Tnf superfamily member 4-1BB-L, 4-1 BBL, CD137L, NP_0038029 TNFSF9, TNLG5AInterferon alpha 1 IFL, IFN, IFN- ALPHA, NP_076918IFNA1, IFNA13, IFNA@,LelF DInterferon beta 1 IFB, IFF, IFN-Beta, IFNB, NP_002167IFNB1Interferon gamma IFG, IFI, IFN, IFN-Gamma, NP_000610IFNG, IMD69Atty Docket No. 3569.W01WO / 680.3569WO01
[0082] In those embodiments wherein the therapeutic protein is or is derived from a cytokine, the cytokine may be CCL21 (NCBI gene ID 6366) or single-chain IL- 12 (derived from IL-12A; NCBI gene ID 3592 and IL-12B; NCBI gene ID 3593).
[0083] In some embodiments, the therapeutic protein is a tumor suppressor. In those embodiments wherein the therapeutic protein is or is derived from a tumor suppressor, the tumor suppressor may be derived from GSDMD (NCBI gene ID 79792), CDKN2A (NCBI gene ID 1029), CDK4 (NCBI gene ID 1019), p53 (NCBI gene ID 7157), PTEN (NCBI gene ID 5728), INK4 (NCBI gene ID 1029), RBI (NCBI gene ID 5925), or APC (NCBI gene ID 324).
[0084] In some embodiments, the therapeutic protein is a checkpoint inhibitor. Checkpoint inhibitors are inhibitors that target key regulators of the immune system. When the key regulators, or immune checkpoints are stimulated they can dampen the immune response to an immunologic stimulus. In those embodiments wherein the therapeutic protein is or is derived from a checkpoint inhibitor, the checkpoint inhibitor may be an antibody fragment, e.g., a scFv, that binds EGFR, NKG2A, PD-1, or PD-L1.
[0085] In those embodiments wherein the therapeutic protein is or is derived from a checkpoint inhibitor, the checkpoint inhibitor may be derived from a commercially available anti-EGFR antibody, antibody fragment, or derivative thereof. Additional information relating to the anti-CD3 antibodies from which the therapeutic protein may be derived are provided at the NCBI and FDA GSRS Accession numbers set forth herein, including, e.g., amivantamab (available under the tradename RYBREVANT; NCBI 6WVZ), cetuximab (available under the tradename ERBITUX; GSRS PQX0D8J21 J), duhgotuzumab (GSRS 8PMF8YQX2T), imgatuzumab (GSRS V77J4WJF9Z), modotuximab (GSRS 1W7BD1M08N), necitumumab (available under the tradename PORTRAZZA; NCBI 6B3S), panitumumab (available under the tradename VECTIBIX; GSRS 6A901E312A), petosemtamab (GSRS Z6Z6IVE7W4), serclutamab (GSRS RY62FD82YX), and zalutumumab (GSRS DA709Q5020).
[0086] In those embodiments wherein the therapeutic protein is or is derived from a checkpoint inhibitor, the checkpoint inhibitor may be derived from a commercially available anti-NKG2A antibody, antibody fragment, or derivative thereof, e.g., monalizumab (GSRS 3ZXZ2V0588).Atty Docket No. 3569.W01WO / 680.3569WO01
[0087] In those embodiments wherein the therapeutic protein is or is derived from a checkpoint inhibitor, the checkpoint inhibitor may be derived from a commercially available anti-PD-1 antibody, antibody fragment, or derivative thereof. Additional information relating to the anti-PD-1 antibodies from which the therapeutic protein may be derived is provided at the FDA GSRS Accession numbers set forth herein, including, e.g., balstilimab (GSRS 1Q2QT5M7EO), budigahmab (GSRS 6VDO4TY3OO), cadomhmab (GSRS 6FYG1DS4NW), cemiplimab (available under the tradename LIBTAYO; GSRS 6QVL057INT), cetrelimab (GSRS LYK98WP91F), dostarlimab (available under the tradename JEMPERLI; GSRS P0GVQ9A4S5), izuralimab (GSRS 9D2R4T39AY), nivolumab (available under the tradename OPDIVO; GSRS nivolumab), pacmilimab (GSRS 31YO63LBSN), pembrolizumab (available under the tradename KEYTRUDA; GSRS DPT0O3T46P), penpulimab (GSRS IBS1BZ4E4I), peresolimab (GSRS DI4N99Q6KK), pidilizumab (GSRS B932PAQ1BQ), retifanlimab (GSRS 2Y3T5IF01Z), rosmlimab (GSRS 93OKX5KD2L), sintihmab (GSRS 8FU7FQ8UPK), spartalizumab (GSRS QOG25L6Z8Z), tislelizumab (GSRS 0KVO411B3N), toripalimab (GSRS 8JXN261WA), volrustomig (GSRS K96EGJ218N), vudalimab (GSRS 4I9I5X3Z6N), zeluvalimab (GSRS DX474PAV6P), and zimberehmab (GSRS ZBL7O904IL).
[0088] In some embodiments, the therapeutic protein is or is derived from a checkpoint inhibitor, the checkpoint inhibitor may be derived from a commercially available anti-PD-Ll antibody, antibody fragment, or derivative thereof. Additional information relating to the anti-PD-Ll antibodies from which the therapeutic protein may be derived are provided at the FDA GSRS Accession numbers set forth herein, including, e.g., atezolizumab (available under the tradename TECENTRIQ; GSRS 52CMI0WC3Y), avelumab (available under the tradename BAVENCIO; GSRS KXG2PJ551I), cosibehmab (GSRS PNW7GBB44P), danburstotug (GSRS F44C4N45HG), durvalumab (GSRS 28X28X9OKV), inbakicept (GSRS QN4LI58PJ5), lodapolimab (GSRS NR4MAD6PPB), pimivalimab (GSRS MA05AF40UO), and socazolimab (GSRS 82P4S8Q3FB).Signal Peptides
[0089] In some embodiments, the nucleic acid coding sequence further includes a sequence that encodes a signal peptide. In some embodiments, these embodiments, the nucleic acid coding sequence encodes a peptide, polypeptide, or protein connected to an in-frame nucleic acidAtty Docket No. 3569.W01WO / 680.3569WO01encoding the signal peptide such that a single, contiguous peptide, polypeptide, or protein is translated. The signal peptide may be 5’ or 3’ to the nucleic acid coding sequence. Therapeutic proteins containing a signal peptide and no transmembrane domain will be secreted from a cell. Therapeutic proteins containing a signal peptide and a transmembrane domain will be transported to the cell membrane. Typically, the signal peptide is cleaved from the protein encoded by the nucleic acid coding sequence before secretion or transport to the cell membrane.
[0090] In some embodiments, the signal peptide is derived from albumin (NCBI gene ID 213), CD8a (NCBI gene ID 925), CD33 (NCBI gene ID 945), erythropoietin (EPO; NCBI gene ID 2056), IL-2 (NCBI gene ID 3558), human Ig-kappa chain V-III (IgK VIII; NCBI gene ID 28912), mouse IgK VIII (NCBI gene ID 667924), tissue plasminogen activator (tPA; NCBI gene ID 5340), or secreted alkaline phosphatase (SEAP; NCBI gene ID 250). Signal peptides may also be synthetic.Therapeutic Nucleic Acids
[0091] In some embodiments, the nucleic acid coding sequence does not encode a translated product (i.e., peptides, polypeptides, or proteins), but instead is therapeutic in its own right by encoding a therapeutic nucleic acid. In some embodiments, the therapeutic nucleic acid is a miRNA. The miRNA is expressed preferentially in ovarian cancer cells relative to non-cancerous ovarian cells and enables the transcriptional unit to express miRNAs that have anti-cancer or immune-stimulating effects. The miRNA may function as tumor suppressors to inhibit cancer cell growth, metastasis, differentiation, regenerative potential, or a combination of two or more thereof. In some embodiments, the miRNA is let-7a, miR-15a, miR-34a, or miR-200.Vectors
[0092] The nucleic acids and gene circuits may be introduced to a cell by a suitable vector. Vectors are configured to contain the elements necessary to effect transport of the synthetic promoter or transcriptional unit into the cell. Such elements may include an origin of replication, a poly-A tail sequence, a selectable marker, and one or more suitable insertion sites for the inclusion of a nucleic acid coding sequence or a transcriptional unit, such as a multiple cloning site (MCS), and additional optional regulatory elements.Atty Docket No. 3569.W01WO / 680.3569WO01
[0093] In some embodiments, the vector contains a synthetic promoter and an insertion site. The vector is therefore suitable for the inclusion of a nucleic acid coding sequence at the insertion site. In some embodiments, the vector contains a transcriptional unit (which contains a synthetic promoter and a nucleic acid coding sequence).
[0094] In some embodiments, the vector is a viral vector, for example, a retroviral vector, a lentiviral vector, an adenoviral vector, a herpesvirus vector, an adenovirus, or an adeno-associated virus (AAV) vector.
[0095] In some embodiments, the vector containing the transcriptional unit is a non-integrative and non-replicative recombinant lentivirus vector. The construction of lentiviral vectors has been described, for example, in U.S. Pat. Nos. 5,665,577 (Sodroski et al.), 5,981,276 (Sodroski et al.), 6,013,516 (Verma et al.), 7,090,837 (Spencer et al.), 8,119,119 (Mallet et al.), and 10,954,530 (Pule et al.). Lentivirus vectors include a defective lentiviral genome, i.e., in which at least one of the lentivirus genes gag, pol, and env, has been inactivated or deleted.
[0096] A lentiviral vector can exhibit functions additional to, or different from, a naturally occurring lentivirus. For example, a lentiviral vector can be modified to change or reduce a lentivirus characteristic. A lentiviral vector also can be modified to exhibit characteristics of one or more other retroviruses, retroviral vectors, host cells or heterologous cells. Modifications can include, for example, pseudotyping, modifying binding and / or fusion functions of the envelope polypeptide, incorporating heterologous, chimeric, or multifunctional polypeptides into the vector, incorporating non- lentivirus genomes, or incorporating heterologous genes into the lentiviral vector genome.
[0097] In some embodiments, the vector containing the transcriptional unit is a Herpes Simplex virus (HSV) vector. Construction of HSV vectors has been described, for example, in U.S. Pat. Nos. 5,849,572 (Glonoso etal.), 6,261,552 (DeLuca), 6,764,675 (Whitley etal.), 7,531,167 (Glorioso et al.), 7,749,745 (Johnson et al.), 10,174,341 (Glorioso et al.), and 10,172,893 (Uchida et al.) and U.S. Pat. App. Pub. Nos. 2019 / 0106709 (Jia et al.), 2020 / 0071679 (Huang et al.), and 2022 / 0213508 (Glorioso et al.).
[0098] In other embodiments, the vector is a non-viral vector, representative examples of which include plasmids, mRNA, linear single stranded (ss) DNA or linear double stranded (ds) DNA, minicircles, and transposon-based vectors, such as Sleeping Beauty (SB)-based vectorsAtty Docket No. 3569.W01WO / 680.3569WO01and piggyBac (PB)-based vectors. In yet other embodiments, the vector may include both viral and non- viral elements.
[0099] In some embodiments the vector is a plasmid. In addition to the nucleic acid sequences corresponding to the nucleic acid or gene circuit, the plasmid may also contain other elements e.g., that facilitate transport and expression of the nucleic acid in an immune cell. The plasmid may be linearized with restriction enzymes, in vitro transcribed to produce mRNA, and then modified with a 5’ cap and 3’ poly-A tail.
[0100] In some embodiments, the vector may be disposed (e.g., encapsulated) in a carrier. The carrier may be lipid- based, e.g., lipid nanoparticles (LNPs), liposomes, lipid vesicles, or lipoplexes. In some embodiments, the carrier is an LNP. In certain embodiments, an LNP includes two or more concentric bilayers separated by aqueous compartments. Lipid bilayers may be functionalized and / or crosslinked to one another. Lipid bilayers may include one or more ligands, proteins, or channels.
[0101] Lipid carriers, e.g., LNPs may include one or more cationic / ionizable lipids, one or more polymer conjugated lipids, one or more structural lipids, and / or one or more phospholipids. A “cationic lipid” refers to positively charged lipid or a lipid capable of holding a positive charge. Cationic lipids include one or more amine group(s) which bear the positive charge, depending on pH. A “polymer conjugated lipid” refers to a lipid with a conjugated polymer portion. Polymer conjugated lipids include a pegylated lipids, which are lipids conjugated to polyethylene glycol. A “structure lipid” refers to a non-cationic lipid that does not have a net charge at physiological pH. Exemplary structural lipids include cholesterol, fecosterol, sitosterol, ergosterol, campesterol, and the like. A “phospholipid” refers to lipids that have a triester of glycerol with two fatty acids and one phosphate ion. Phospholipids in LNPs assemble the lipids into one or more lipid bilayers. LNPs, their method of preparation, formulation, and delivery are disclosed in, e.g., U.S. Pat. App. Pub. Nos. 2004 / 0142025 (Maclachlan etal.), 2007 / 0042031 (Maclachlan et al.), and 2020 / 0237679 (Kaufman) and U.S. Pat. Nos. 9,364,435 (Yaworski et al.), 9,518,272 (Yaworski et al.), 10,022,435 (Ciaramella et al.), and 11,191,849 (Abrams et al.).
[0102] Lipoplexes, liposomes, and lipid nanoparticles may include a combination of lipid molecules, e.g., a cationic lipid, a neutral lipid, an anionic lipid, polypeptide-lipid conjugates, and other stabilization components. Representative stabilization components include antioxidants, surfactants, and salts. Compositions and preparation methods of lipoplexes,Atty Docket No. 3569.W01WO / 680.3569WO01liposomes, and lipid nanoparticles are known in the art. See, e.g., U.S. Pat. Nos. 8,058,069 (Yaworski et al.), 8,969,353 (Mahon et al.), 9,682,139 (Manoharan et al.), 10,238,754 (Guild et al.), and U.S. Pat. App. Pub. Nos. 2005 / 0064026 (Gandel et al.) and 2018 / 0291086 (Anchordoquy et al.), and Lasic, Trends Biotechnol. 16(7):307-21 (1998), Lasic et al., FEBS Lett. 312(2-3):255-8 (1992), and Drummond et al., Pharmacol. Rev. 51(4):691-743 (1999).Methods of Treating
[0103] In another aspect, the present disclosure relates to methods of treating a subject, such as a patient. Typically, the subject is in need of treatment for ovarian cancer. The subject may have or be at risk of having ovarian cancer.
[0104] Typically, the therapeutic output expressed by the nucleic acid, gene circuit, or vector is useful in treatment of ovarian cancer. When ovarian cancer- specific promoters are used, expression of the therapeutic output in non-ovarian cancer cells, such as healthy ovarian cells, is typically lower than expression of the therapeutic output in ovarian cancer cells. Thus, the therapeutic output is typically expressed to a higher level in ovarian cancer cells than in other cells, such as healthy or normal ovarian cells.
[0105] Because the methods described herein typically result in targeting treatment to ovarian cancer cells, side effects may be reduced. Methods of treating described herein may result in fewer side effects than standard methods of treating ovarian cancer (FIG. 11).
[0106] For therapeutic use, administration of an agent can begin at the detection or surgical removal of tumors. This can be followed by boosting doses until at least symptoms are substantially abated and for a period thereafter.
[0107] The pharmaceutical compositions for therapeutic treatment are intended for parenteral, topical, nasal, oral or local administration. Preferably, the pharmaceutical compositions are administered parenterally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. The disclosure provides compositions for parenteral administration which comprise a solution of a suitable agent dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, e.g., water, buffered water, saline, glycine, hyaluronic acid, and the like. These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterileAtty Docket No. 3569.W01WO / 680.3569WO01solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents, and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.
[0108] In an advantageous embodiment, the cancer therapeutic is an immunotherapeutic (e.g., an antibody). The cancer therapeutic can be a chimeric antigen receptor (CAR) T cell. The immunotherapeutic may be a cytokine therapeutic (such as an interferon or an interleukin), a dendritic cell therapeutic or an antibody therapeutic, such as a monoclonal antibody. In a particularly advantageous embodiment, the immunotherapeutic is a neoantigen (see, e.g., U.S. Pat. No. 9,115,402 and U.S. Pat. App. Pub. Nos. 20110293637, 20160008447, 20160101170, 20160331822 and 20160339090).
[0109] The practice of the present methods employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are well within the purview of the skilled artisan. Such techniques are explained fully in the literature, such as, “Molecular Cloning: A Laboratory Manual”, second edition (Sambrook, 1989); “Oligonucleotide Synthesis” (Gait, 1984); “Animal Cell Culture” (Freshney, 1987); “Methods in Enzymology” “Handbook of Experimental Immunology” (Weir, 1996); “Gene Transfer Vectors for Mammalian Cells” (Miller and Calos, 1987); “Current Protocols in Molecular Biology” (Ausubel, 1987); “PCR: The Polymerase Chain Reaction”, (Mullis, 1994); “Current Protocols in Immunology” (Coligan, 1991). These techniques are applicable to the production of the polynucleotides and polypeptides of the disclosure, and, as such, may be considered in making and practicing the methods.Pharmaceutical Compositions
[0110] Pharmaceutical compositions include effective amounts of the vector containing the nucleic acid or gene circuit and a pharmaceutically acceptable carrier. The amount of vector in the pharmaceutical composition administered to a subject will vary between wide limits, depending upon one or more factors that may include the location, type, and severity of the cancer, the age, body weight, and condition of the individual to be treated. A physician will ultimately determine appropriate doses to be used.Atty Docket No. 3569.W01WO / 680.3569WO01
[0111] Compositions may be provided as sterile lyophilized or liquid preparations.Lyophilized preparations may be reconstituted and diluted into a liquid preparation before use, e.g., with carriers containing isotonic aqueous solutions, suspensions, emulsions, dispersions, or viscous solutions, which may be buffered to a selected pH. Liquid carriers include aqueous or non-aqueous carriers alike. Representative examples of liquid carriers include sterile water for injection, saline, Lactated Ringer Injection solution, phosphate buffered saline, a soluble protein, soluble sugars (e.g., dextrose), dimethyl sulfoxide (DMSO), polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol, and the like), ethanol, and suitable mixtures thereof. In some embodiments, the liquid carrier includes a protein dissolved or dispersed therein, representative examples include serum albumin (e.g., human serum albumin, recombinant human albumin), gelatin, and casein. The compositions are typically isotonic, i.e., they have the same osmotic pressure as blood. Citric acid, sodium chloride, sugars, polyalcohols, and isotonic electrolyte solutions (e.g., the solution available under the tradename PLASMA-LYTE) may be used to achieve the desired isotonicity. Depending on the carrier, and the vector other excipients may be added, e.g., wetting, dispersing, or emulsifying agents, gelling and viscosity enhancing agents, preservatives and the like as known in the art. In some embodiments, the compositions include the vector, sucrose, polysorbate-20, potassium chloride, potassium phosphate, sodium chloride, and sodium phosphate. In some embodiments, the composition is further diluted in a 0.9% normal saline solution.
[0112] Additional pharmaceutically acceptable excipients used in the manufacture of pharmaceutical compositions, their formulation, and delivery of expression vectors such as viral vectors are known in the art. See, for example, U.S. Pat. App. Pub. Nos. 2013 / 0090374 (Sena-Esteves et al.), and 2012 / 0309050 (Kumon et al.), and U.S. Pat. Nos. 7,858,367 (Amalfitano et al.), 11,020,443 (Sena-Esteves etal.), and 11,041,171 (Gao etal.).Administration
[0113] In another aspect, a method of treating ovarian cancer includes administering to a subject in need thereof an effective amount of a nucleic acid, a gene expression vector, or a gene circuit of described herein.
[0114] The amount of pharmaceutical composition containing the vector administered to an ovarian cancer cell or subject may vary between wide limits. In embodiments where the ovarianAtty Docket No. 3569.W01WO / 680.3569WO01cancer cell is contacted with the vector in vitro, the effective amount of the vector is between approximately 0.3 to approximately 5 genome copies (gc) per cell.
[0115] Pharmaceutical compositions containing an effective amount of the vector may be brought into contact with an ovarian cancer cell in vivo by any medically acceptable route. In some embodiments, the pharmaceutical compositions are administered to a subject for the treatment of ovarian cancer. The pharmaceutical composition is may often be delivered intravenously or intraperitoneally, although they may also be introduced into other convenient sites (e.g., intratumorally to an affected organ or tissue) or modes, as determined by an attending physician.
[0116] In some embodiments, the pharmaceutical composition is administered as an infusion (e.g., intravenously, or intraperitoneally) to the subject over a predetermined period of time. Representative infusion times are 30 minutes, 60 minutes, 90 minutes, and 120 minutes. In some embodiments, the infusion time is between 60 and 120 minutes. In some embodiments, the pharmaceutical composition is administered intratumorally. Representative intratumoral injection volumes are 0.1 milliliter (mL), 0.2 mb, 0.3 mL, 0.4 mL, 0.5 mL, 1 mb, 2 mb, 5 mL, and 10 mb
[0117] In some embodiments, where the ovarian cancer cell is contacted with the vector in vivo, as in a subject to be treated, the amount of pharmaceutical composition or vector will vary between wide limits, depending on factors that may include the location, type, and severity of the ovarian cancer, the age, body weight, and condition of the individual to be treated. A physician will ultimately determine appropriate amount of vector to be used. Typically, the vector will be given in a single dose. In some embodiments, an effective amount of the vector in the pharmaceutical composition may range from approximately! x 106to approximately 5 x 1014gc per kg body weight (gc / kg). In some embodiments, the effective amount of the vector in the pharmaceutical composition may range from approximately 1 x 1010to approximately 2 x 1013gc / kg. In some embodiments, the effective amount of the vector in the pharmaceutical composition is approximately 2 x 1013gc / kg. In some embodiments, the vector may be administered at a dose of 10xl010to 1 xlO13gc per subject. In some embodiments, the effective amount of the vector in the pharmaceutical composition is approximately 1 x 107gc per subject. In some embodiments, the effective amount of the vector in the pharmaceutical composition is approximately 2 x 108gc per subject. In some embodiments, the effective amount of the vector in the pharmaceutical composition is approximately 1 x 109gc per subject. In someAtty Docket No. 3569.W01WO / 680.3569WO01embodiments, the effective amount of the vector in the pharmaceutical composition is approximately 1.5 x 1011gc per subject.Combination Therapy
[0118] In some embodiments, the method includes delivering a vector, nucleic acid, or gene circuit encoding a therapeutic output that confers sensitivity to a drug or an immunotherapeutic agent. The method typically further comprises administering to the patient the drug or immunotherapeutic agent. In this way, cells of interest may be combinatorially targeted by the specificity of the vector, nucleic acid, or gene circuit and the drug or immunotherapeutic agent.
[0119] In some embodiments, the present methods may include co-administration of the pharmaceutical composition along with one or more anti-cancer agents. The term “coadministered” includes substantially contemporaneous administration, by the same or separate dosage forms, or sequentially, e.g., as part of the same treatment regimen or by way of successive treatment regimens. The sequence and time interval may be determined such that the co-administered therapies can act together (e.g., synergistically to provide an increased benefit than if they were administered otherwise). For example, the therapeutics may be administered at the same time or sequentially in any order at different points in time; however, if not administered at the same time, they may be administered sufficiently close in time so as to provide the desired therapeutic effect, which may be in a synergistic fashion.
[0120] Anti-cancer agents that may be used in combination with the inventive pharmaceutical compositions are known in the art. See, e.g., U.S. Pat. No. 9,101,622 (Zeldis; Section 5.2 thereof). An “anti-cancer” agent is capable of negatively affecting cancer in a subject, for example, by killing cancer cells, inducing apoptosis in cancer cells, reducing the growth rate of cancer cells, reducing the incidence or number of metastases, reducing tumor size, inhibiting tumor growth, reducing the blood supply to a tumor or cancer cells, promoting an immune response against cancer cells or a tumor, preventing or inhibiting the progression of cancer, or increasing the lifespan of a subject with cancer.
[0121] In some embodiments, the provided methods are used before, in conjunction with, or following therapies known in the art, such as chemotherapeutic, radiotherapeutic, immunotherapeutic intervention, targeted therapy, pro-apoptotic therapy, or cell cycle regulation therapy.Atty Docket No. 3569.W01WO / 680.3569WO01
[0122] These and other aspects of the present application will be further appreciated upon consideration of the following Examples, which are intended to illustrate certain embodiments of the application but are not intended to limit its scope, as defined by the claims.EXAMPLES
[0123] Examples are provided below to facilitate a more complete understanding of the disclosure. The following examples illustrate the exemplary modes of making and practicing what is disclosed. However, the scope of the disclosure is not limited to specific embodiments disclosed in these Examples, which are for purposes of illustration only, since alternative methods can be utilized to obtain similar results.EXAMPLE 1- Identifying ovarian cancer-specific promoters
[0124] In this Example, the strength of different promoters was tested in ovarian cancer cell lines. 19 promoters were selected and tested for expression strength (measured as fluorescence intensity) in IOSE and OV8 cells. IOSE cells were chosen to be representative of normal ovarian epithelial cells. OV8 cells were chosen to be representative of ovarian cancer cells. Lentiviral vectors containing various promoters driving GFP expression were used to infect OV8 (tumor) and IOSE (normal) cells. Flow cytometry was performed to quantify fluorescence intensity, using the median fluorescence intensity (MFI) for analysis. Data were normalized to the activity of the constitutive human Ubiquitin C (UBC) promoter. The tumor / normal ratio was calculated by dividing the normalized MFI of OV8 cells by that of IOSE cells. The strength of expression of each promoter was compared between cell lines. The strength of each promoter and its relative tumor specificity is shown in FIG. 1. The MYC_v4, TFEB, TFDP1, and E2F2_v2 promoters were found to have the best specificity for tumor cells (FIG. 1).
[0125] The two promoters with the highest tumor specificity (MYC-v4 and TFEB) were tested for expression in OV8 and IOSE cells. Fluorescence and brightfield microscopy were used to analyze cells treated with a construct designed to express a fluorescent protein under control of each promoter. OV8 cells treated with either construct showed relatively high fluorescence, while IOSE cells treated with either construct showed minimal, if any, fluorescence.Atty Docket No. 3569.W01WO / 680.3569WO01
[0126] It was observed that promoter constructs selectively responded to their cognate transcription factors. Two MYC-responsive promoters (CC63_MYC_v2 and CC65_MYC_v4) were found to exhibit increased output activity upon MYC overexpression, whereas an E2F-responsive promoter (CC83_E2F_v2) was not, indicating that CC63_MYC_v2 and CC65_MYC_v4 were selectively responsive to MYC. (FIG. 2A). In addition, the E2F-responsive promoter (CC83_E2F_v2) exhibited increased output activity upon E2F overexpression, while the MYC-responsive promoters (CC63_MYC_v2 and CC65_MYC_v4) did not, indicating that the CC83_E2F_v2 promoter exhibited specificity for E2F (FIG. 2B).EXAMPLE 2- Development of split GAD for use in gene circuits.
[0127] While several promoters with specificity to ovarian cancer cells, rather than normal cells, were identified in Example 1 , it was desired to combine the specificity of more than one promoter to further increase the specificity. To achieve this goal, an AND gate that required activity of two promoters in a single cell was desired. A split activator utilizing the GAD activator / promoter system was prepared for use as an AND gate. As is described above in greater detail, the term “GAD” refers to a fusion protein comprising the Gal4 DNA-binding domain (Gal4BD) and the VP16 transcriptional activation domain (AD). Several configurations of the split GAD system were tested (FIG. 3A). In these designs, the Gal4 DNA-binding domain (Gal4BD) was separated from the activation domain (AD), and complementary SYNZIP sequences were fused to facilitate reconstitution of the activator. Specifically, the SYNZIP sequence was fused to the N-terminus of Gal4BD and the C-terminus of AD (N-C configuration), to the C-terminus of both Gal4BD and AD (C-C configuration), or to the N-terminus of both proteins (N-N configuration). Each fusion protein was expressed from a CMV promoter to maximize expression. Upon expression of both halves and successful assembly, a fluorescent protein under the control of the GAD promoter would be expressed (FIG. 3A). It was found that the N-C architecture resulted in an order of magnitude higher fluorescence intensity than either the N-N or the C-C architecture (FIG. 3A). Thus, the N-C architecture was used moving forward to express the split GAD protein.
[0128] Next, cells were treated with either half of the split GAD protein or both halves together. All cells had a nucleic acid configured to express mKate under the GAD promoter. In cells containing both halves of the split GAD activator, fluorescence was observed, indicatingAtty Docket No. 3569.W01WO / 680.3569WO01successful assembly of the full GAD activator and expression of mKate from the GAD promoter (FIG. 3B). In cells treated with either half of the split GAD activator, no expression was observed, indicating that both halves were necessary for expression of mKate from the GAD promoter (FIG. 3B).
[0129] Next, the split N-C GAD activator was expressed with different pairs of SYNZIP protein dimerization domains. Two pairs of SYNZIP dimerization domains were tested in OV8 and BPPNM cells: SYNZIP 1 / SYNZIP2 and SYNZIP5 / SYNZIP12. It was found that SYNZIP5 / SYNZIP12 resulted in much higher expression in both OV8 and BPPNM cells (FIG.4A). Fluorescence microscopy and brightfield images of OV8 and IOSE cells treated with the split N-C GAD activator including the SYNZIP5 / SYNZIP12 dimerization domain are shown in FIG. 4B.
[0130] From this Example, it was determined that the N-C architecture resulted in the strongest expression from the GAD promoter, and that both halves of the split N-C GAD activator were required for expression of a gene from the GAD promoter. In addition, it was determined that the SYNZIP5 / 12 pair resulted in the strongest expression in OV8 and IOSE cells.EXAMPLE 3- Development of ovarian cancer-specific gene circuits using split GAD and ovarian cancer-specific promoters.
[0131] In this Example, the split N-C GAD SYNZIP5 / 12 activator was tested with different pairs of ovarian cancer-specific promoters. The promoters CC65 MYC (MYC_v4 in FIG. 1), CC55 E2F7 (E2F7_v3 in FIG. 1), CC63_myc (MYC_v2 in FIG. 1), CC83_E2F (E2F_v2 in FIG. 1), CC2 FOS, and CC31 BACH1. Each half of the split N-C GAD activator was expressed from a different promoter, thereby requiring expression of both promoters for expression and assembly of the active GAD activator. Each composition of nucleic acids used to express the split GAD activator and the fluorescent protein output was considered to be a different gene circuit. The activity of each gene circuit was tested in OV8 and IOSE cells. None of the tested circuits showed appreciable activity in IOSE cells (FIG. 5B). The circuit employing the CC55 E2F7 promoter to drive Gal4BD expression and the CC65 MYC promoter to drive VP16AD expression exhibited the strongest activity in OV8 cells (FIG. 5A). The ratio of activity in OV8 to IOSE cells for each gene circuit is shown in FIG. 6A. The following circuits allAtty Docket No. 3569.W01WO / 680.3569WO01demonstrated high OV8 / IOSE specificity: (1) CC83 E2F7 driving Gal4BD and CC63 MYC driving VP16AD; (2) CC83_E2F7 driving Gal4BD and CC65 MYC driving VP16AD; (3) CC63 MYC driving Gal4BD and CC83_E2F7 driving VP16AD; (4) CC63 MYC driving Gal4BD and CC55 E2F7 driving VP16AD; (5) CC55 E2F7 driving Gal4BD and CC63 MYC driving VP16AD; (6) CC55_E2F7 driving Gal4BD and CC65 MYC driving VP16AD; (7) CC65 MYC driving Gal4BD and CC83_E2F7 driving VP16AD; and (8) CC65 MYC driving Gal4BD and CC55 E2F7 driving VP16AD. Among these, the circuit utilizing the CC55 E2F7 promoter to drive Gal4BD expression and the CC65 MYC promoter to drive VP 16 D expression exhibited the highest OV8-to-IOSE specificity, achieving over a 1000-fold difference (FIG. 6B).EXAMPLE 4- Testing ovarian cancer-specific gene circuits in mouse model of ovarian cancer
[0132] In this Example, the construct including the CC63 MYC promoter to drive Gal4BD expression and the CC72 ZBTB33 promoter to drive VP16AD expression (referred to herein as the “gene circuit”) was used to treat mice with an implanted ovarian cancer tumor. Different outputs were expressed under control of the G8P promoter to test which would have the strongest anti-tumor effect.
[0133] C57BL / 6J mice were subcutaneously injected with 2 106BPPNM cells to form a tumor. Eight days after tumor implantation, mice were treated with a lentivirus encoding the gene circuit including a therapeutic output, a gene circuit without a therapeutic output, or PBS. Seven outputs were tested, including different antitumor effectors or EGFP (GR1-7 of FIG. 10). Mice treated with the EGFP-expressing lentivirus and mice treated with the PBS served as control groups. Each lentivirus was injected intraperitoneally.
[0134] Beginning on day 11, mice were imaged weekly to determine tumor burden. Survival rates of mice treated with each gene circuit were tracked. Mice treated with the gene circuit expressing STE, CD80, IL12, and anti-PDl(Gr4, labeled “S8IP”) exhibited significantly smaller tumor burden and significantly improved survival rates (FIG. 8). Tumor b as measured by luminescence for mice treated with each gene circuit is shown in FIG. 9, and luminescence images of mice treated in each group are shown in FIG. 10.Atty Docket No. 3569.W01WO / 680.3569WO01EMBODIMENTS
[0135] Embodiment 1 is a nucleic acid for use in treating ovarian cancer including:a first nucleic acid sequence encoding a first half of a transcription factor under the control of a first ovarian cancer-specific promoter;a second nucleic acid sequence encoding a second half of the transcription factor under the control of a second ovarian cancer-specific promoter,wherein the first half of the transcription factor and the second half of the transcription factor assemble to form an active transcription factor; anda third nucleic acid sequence encoding a therapeutic output that is only expressed in the presence of the active transcription factor.
[0136] Embodiment 2 is the nucleic acid of embodiment 1 , wherein the first ovarian cancerspecific promoter includes a nucleic acid sequence having least 80% sequence identity to the CC63 MYC promoter (SEQ ID NO: 1), the CC83 E2F promoter (SEQ ID NO:2), the CC55 E2F7 promoter (SEQ ID NO: 3), the CC65 MYC promoter (SEQ ID NO:4), or the CC72 ZBTB33 promoter (SEQ ID NO: 5).
[0137] Embodiment 3 is the nucleic acid of embodiment 1 or embodiment 2, wherein the second ovarian cancer-specific promoter includes a nucleic acid sequence having least 80% sequence identity to the CC63 MYC promoter (SEQ ID NO: 1), the CC83 E2F promoter (SEQ ID NO: 2), the CC55 E2F7 promoter (SEQ ID NO: 3), the CC65 MYC promoter (SEQ ID NO:4), or the CC72 ZBTB33 promoter (SEQ ID NO: 5); andwherein the first ovarian cancer-specific promoter includes at most 80% sequence identity to the second ovarian cancer- specific promoter.
[0138] Embodiment 4 is the nucleic acid of any preceding embodiment, wherein the first ovarian cancer-specific promoter includes a nucleic acid sequence having least 90% sequence identity to the CC55 E2F7 promoter (SEQ ID NO: 3) and the second ovarian cancer-specific promoter includes a nucleic acid sequence having at least 90% identity to the CC63 MYC promoter (SEQ ID NO:1).
[0139] Embodiment 5 is the nucleic acid of any preceding embodiment, wherein the therapeutic output is under the control of the GALp promoter (SEQ ID NO:6).6 is the nucleic acid of any preceding embodiment, wherein the active transcription factor includes an amino acid sequence having at least 80% sequence identity to the Gal4BD domain (SEQ ID NO: 8).Atty Docket No. 3569.W01WO / 680.3569WO01
[0140] Embodiment 7 is the nucleic acid of any preceding embodiment, wherein the active transcription factor includes an amino acid sequence having at least 80% sequence identity to the Gal4 Activation Domain (AD) (SEQ ID NO:9).
[0141] Embodiment 8 is the nucleic acid of any preceding embodiment, wherein the first half of the transcription factor includes a first dimerization domain at its C terminus.
[0142] Embodiment 9 is the nucleic acid of any preceding embodiment, wherein the second half of the transcription factor includes a second dimerization domain at its N terminus.
[0143] Embodiment 10 is the nucleic acid of any preceding embodiment, wherein the second half of the transcription factor includes a nuclear localization signal including an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 9.
[0144] Embodiment 11 is the nucleic acid of any preceding embodiment, wherein the first half of the transcription factor includes an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 10 and the second half of the transcription factor includes an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 11.
[0145] Embodiment 12 is the nucleic acid of any preceding embodiment, wherein the therapeutic output confers sensitivity to a drug or an immunotherapeutic agent.
[0146] Embodiment 13 is the nucleic acid of any preceding embodiment, wherein the therapeutic output includes CD80, IL-12, CCL21, or a Surface T cell Engager (STE).
[0147] Embodiment 14 is a gene expression vector including the nucleic acid of any preceding embodiment.
[0148] Embodiment 15 is the gene expression vector of embodiment 14, wherein the gene expression vector includes a plasmid or a virus.
[0149] Embodiment 16 is a gene circuit including the nucleic acid of embodiment 1.
[0150] Embodiment 17 is a method of treating ovarian cancer including administering to a patient in need thereof an effective amount of (a) the nucleic acid of any one of embodiments 1 -13, the gene expression vector of embodiment 14 or 15, or the gene circuit of embodiment 16.
[0151] Embodiment 18 is the method of embodiment 17, wherein the therapeutic output confers sensitivity to a drug or an immunotherapeutic agent, and wherein the method further includes administering to the patient the drug or immunotherapeutic agent.Atty Docket No. 3569.W01WO / 680.3569WO01
[0152] Embodiment 19 is the method of embodiment 17 or embodiment 18, wherein the first ovarian cancer-specific promoter and / or the second ovarian cancer-specific promoter is more active in ovarian cancer cells than in normal ovarian cells.
[0153] Embodiment 20 is the method of any one of embodiments 17-19, wherein the therapeutic output is expressed to a higher level in ovarian cancer cells than in normal ovarian cells.SEQUENCE LISTING FREE TEXT SEQ ID NO: 1- CC63 MYC promoter CCACGTGCTTAGACCACGTGCTTTCGCCACGTGCTTGACCCACGTGCTTATACCACG TGCTTACTCCACGTGCTTTACCCACGTGCTTTAGCCACGTGCTTCATCCACGTGCTTG GCGCGCCAGACGCTAGCGGGGGGCTATAAAAGGGGGTGGGGGCGTTCGTCCTCACT CTSEQ ID NO 2- CC83 E2F promoter TTTCGCGCCAAAAGATTTCGCGCCAAATCGTTTCGCGCCAAAGACTTTCGCGCCAAA ATATTTCGCGCCAAAACTTTTCGCGCCAAATACTTTCGCGCCAAATAGTTTCGCGCC AAAGGCGCGCCAGACGCTAGCGGGGGGCTATAAAAGGGGGTGGGGGCGTTCGTCCT CACTCTSEQ ID NO: 3- CC55 E2F7 promoter ATTTCCCGCCAATTAGAATTTCCCGCCAATTTCGATTTCCCGCCAATTGACATTTCCC GCCAATTATAATTTCCCGCCAATTACTATTTCCCGCCAATTTACATTTCCCGCCAATT GGCGCGCCAGACGCTAGCGGGGGGCTATAAAAGGGGGTGGGGGCGTTCGTCCTCAC TCTSEQ ID NO:4- CC65 MYC promoter CACGTGCAGACACGTGCTCGCACGTGCGACCACGTGCATACACGTGCACTCACGTG CTACCACGTGCTAGCACGTGCCATCACGTGCATCCACGTGCGATCACGTGCCGTCAC GTGCGGCGCGCCAGACGCTAGCGGGGGGCTATAAAAGGGGGTGGGGGCGTTCGTCCAtty Docket No. 3569.W01WO / 680.3569WO01SEQ ID NO: 5- CC72 ZBTB33 promoter TCTCGCGACAAGATCTCGCGACATCGTCTCGCGACAGACTCTCGCGACAATATCTCG CGACAACTTCTCGCGACATACTCTCGCGACATAGTCTCGCGACACATTCTCGCGACA GGCGCGCCAGACGCTAGCGGGGGGCTATAAAAGGGGGTGGGGGCGTTCGTCCTCAC TCTSEQ ID NO: 6- GALp promoter CGATAGGTACCGAGTTTCTAGACGGAGTACTGTCCTCCGAGCGGAGTACTGTCCTCC GACTCGAGCGGAGTACTGTCCTCCGATCGGAGTACTGTCCTCCGCGAATTCCGGAGT ACTGTCCTCCGAAGACGCTAGACGGAGTACTGTCCTCCGAGCGGAGTACTGTCCTCC GACTCGAGCGGAGTACTGTCCTCCGGCTAGCGGGGGGCTATAAAAGGGGGTGGGGG CGTTCGTCCTCACTCTAGATCTGCGATCTAAGTAAGCTTGGCATTCCGGTACTGSEQ ID NO: 7- VP 16 transactivating domain (AD) MKLLSSIEQACPKKKRKVDEFPGISTAPPTDVSLGDELHLDGEDVAMAHADALDDFDLD MLGDGDSPGPGSEQ ID NO: 8- Gal4BD MKLLSSIEQACDICRLKKLKCSKEKPKCAKCLKNNWECRYSPKTKRSPLTRAHLTEVES RLERLEQLFLLIFPREDLDMILKMDSLQDIKALLTGLFVQDNVNKDAVTDRLASVETDM PLTLRQHRIS ATS S SEES SNKGQRQLTVSSEQ ID NOV- NLS from VP16ADgMKLLS SIEQ ACPKKKRKVDSEQ ID NO: 10- Gal4BD-SZ5 MKLLSSIEQACDICRLKKLKCSKEKPKCAKCLKNNWECRYSPKTKRSPLTRAHLTEVES RLERLEQLFLLIFPREDLDMILKMDSLQDIKALLTGLFVQDNVNKDAVTDRLASVETDM PLTLRQHRIS ATS S SEES S NKGQRQLTVS EFNTVKELKNYIQELEERN A ELI<NLI<EHLI<F AKAELEFELAAHKFEEF*Atty Docket No. 3569.W01WO / 680.3569WO01SEQ ID NO:11- SZ12-AD MNEDLVLENRLAALRNENAALENDLARLEI<EIAYLEI<EIEREI<STAPPTDVSLGDELHL DGEDVAMAHADALDDFDLDMLGDGDSPGPGSEQ ID NO:12- SZ5 NTVI<ELI<NYIQELEERNAELI<NLI<EHLI<FAI<AELEFELAAHI<FEEFSEQ ID NO:13- SZ12 MNEDLVLENRLAALRNENAALENDLARLEI<EIAYLEI<EIEREI<SEQ ID NO: 14- SYNZIP12-AD-NLS MNEDLVLENRLAALRNENAALENDLARLEI<EIAYLEI<EIEREI<EFMI<LLSSIEQACPI<I< KRKVDEFPGISTAPPTDVSLGDELHLDGEDVAMAHADALDDFDLDMLGDGDSPGPG
[0154] Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein. Such equivalents are considered to be within the scope of this disclosure. The foregoing discussion discloses and describes merely exemplary arrangements of the present teachings. Furthermore, the mixing and matching of features, elements and / or functions between various embodiments is expressly contemplated herein, so that one of ordinary skill in the art would appreciate from this disclosure that features, elements and / or functions of one embodiment may be incorporated into another embodiment as appropriate, unless described otherwise above. Moreover, many modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the essential scope thereof. One skilled in the art will readily recognize from such discussion, and from the accompanying drawings and claims, that various changes, modifications and variations can be made therein without departing from the spirit and scope of the present teachings as defined in the following claims.
Claims
Atty Docket No. 3569.W01WO / 680.3569WO01CLAIMSWhat is claimed:
1. A nucleic acid for use in treating ovarian cancer comprising:a first nucleic acid sequence encoding a first half of a transcription factor under the control of a first ovarian cancer-specific promoter;a second nucleic acid sequence encoding a second half of the transcription factor under the control of a second ovarian cancer-specific promoter,wherein the first half of the transcription factor and the second half of the transcription factor assemble to form an active transcription factor; anda third nucleic acid sequence encoding a therapeutic output that is only expressed in the presence of the active transcription factor.
2. The nucleic acid of claim 1, wherein the first ovarian cancer-specific promoter comprises a nucleic acid sequence having least 80% sequence identity to the CC63 MYC promoter (SEQ ID NO: 1), the CC83 E2F promoter (SEQ ID NO:2), the CC55 E2F7 promoter (SEQ ID NO:3), the CC65 MYC promoter (SEQ ID NO:4), or the CC72 ZBTB33 promoter (SEQ ID NO:5).
3. The nucleic acid of claim 2, wherein the second ovarian cancer- specific promoter comprises a nucleic acid sequence having least 80% sequence identity to the CC63_MYC promoter (SEQ ID NO:1), the CC83 E2F promoter (SEQ ID NO:2), the CC55 E2F7 promoter (SEQ ID NO:3), the CC65 MYC promoter (SEQ ID NO:4), or the CC72 ZBTB33 promoter (SEQ ID NO:5); andwherein the first ovarian cancer-specific promoter comprises at most 80% sequence identity to the second ovarian cancer- specific promoter.
4. The nucleic acid of claim 3, wherein the first ovarian cancer-specific promoter comprises a nucleic acid sequence having least 90% sequence identity to the CC55 E2F7 promoter (SEQ ID NO: 3) and the second ovarian cancer-specific promoter comprises a nucleic acid sequence having at least 90% identity to the CC63 MYC promoter (SEQ ID NO:1).Atty Docket No. 3569.W01WO / 680.3569WO015. The nucleic acid of any one of claims 1-4, wherein the therapeutic output is under the control of the GALp promoter (SEQ ID NO: 6).
6. The nucleic acid of any one of claims 1-4, wherein the active transcription factor comprises an amino acid sequence having at least 80% sequence identity to the Gal4BD domain (SEQ ID NO:8).
7. The nucleic acid of any one of claims 1-4, wherein the active transcription factor comprises an amino acid sequence having at least 80% sequence identity to the Gal4 Activation Domain (AD) (SEQ ID NO:9).
8. The nucleic acid of any one of claims 1-4, wherein the first half of the transcription factor comprises a first dimerization domain at its C terminus.
9. The nucleic acid of any one of claims 1-4, wherein the second half of the transcription factor comprises a second dimerization domain at its N terminus.
10. The nucleic acid of any one of claims 1-4, wherein the second half of the transcription factor comprises a nuclear localization signal comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 9.
11. The nucleic acid of any one of claims 1 -4, wherein the first half of the transcription factor comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NOTO and the second half of the transcription factor comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 11.Atty Docket No. 3569.W01WO / 680.3569WO0112. The nucleic acid of any one of claims 1-4, wherein the therapeutic output confers sensitivity to a drug or an immunotherapeutic agent.
13. The nucleic acid of any preceding claim, wherein the therapeutic output comprises CD80, IL- 12, CCL21, or a Surface T cell Engager (STE).
14. A gene expression vector comprising the nucleic acid of any one of claims 1 -4.
15. The gene expression vector of claim 14, wherein the gene expression vector comprises a plasmid or a virus.
16. A gene circuit comprising the nucleic acid of claim 1.
17. A method of treating ovarian cancer comprising administering to a patient in need thereof an effective amount of (a) the nucleic acid of any one of claims 1-4, the gene expression vector of claim 14 or 15, or the gene circuit of claim 16.
18. The method of claim 17, wherein the therapeutic output confers sensitivity to a drug or an immunotherapeutic agent, and wherein the method further comprises administering to the patient the drug or immunotherapeutic agent.
19. The method of claim 17 or claim 18, wherein the first ovarian cancer-specific promoter and / or the second ovarian cancer-specific promoter is more active in ovarian cancer cells than in normal ovarian cells.
20. The method of any one of claims 17-19, wherein the therapeutic output is expressed to a higher level in ovarian cancer cells than in normal ovarian cells.
